Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating expenses in 2025. Encouraging long-term cardiopulmonary data from the DELIVER ...
5hon MSN
What does the appendix do? Biologists explain the complicated evolution of this inconvenient organ
Most people know only two things about the appendix: You don’t need it – and if it bursts, you need surgery fast. That basic ...
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results